Successful Treatment of Paraneoplastic Cholestasis in Relapsed/Refractory Hodgkin ’s Lymphoma with Bridging Therapy and Checkpoint Blockade
Paraneoplastic cholestasis is a rare manifestation of Hodgkin ’s lymphoma (HL), especially in the relapsed/refractory setting. Outcomes are generally poor, perhaps related to the narrow therapeutic window of standard chemotherapy drugs in patients with compromised liver function and limited activity of radiotherapy in controlling systemic disease. Here, we p resent the first report of successful treatment of a patient with idiopathic cholestasis in the setting of relapsed HL post autologous stem cell transplant (ASCT) with bridging therapy (cyclophosphamide, methylprednisolone) and sequential nivolumab.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Gopisree Peringeth, Pallawi Torka, Jerry Wong, Francisco J. Hernandez-Ilizaliturri Tags: Case Report Source Type: research
More News: Chemotherapy | Cholestasis | Hematology | Hodgkin's Disease | Leukemia | Liver | Liver Transplant | Lymphoma | Methylprednisolone | Myeloma | Paraneoplastic Syndrome | Stem Cell Therapy | Stem Cells | Transplant Surgery | Transplants | Urology & Nephrology